Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zexuan Liu

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Neuro-Oncology Advances|September 6, 2021
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastomaUday P Pratap, Gangadhara R Sareddy, Zexuan Liu, et al.
Science (New York, N.Y.)|June 27, 2020
Metalens-array-based high-dimensional and multiphoton quantum sourceLin Li, Zexuan Liu, Xifeng Ren, et al.
Breast Cancer Research : BCR|April 9, 2022
SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistanceZexuan Liu, Junhao Liu, Behnam Ebrahimi, et al.
Molecular Oncology|October 19, 2023
PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesisXue Yang, Zexuan Liu, Weiwei Tang, et al.
Cancers|November 11, 2022
Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer GrowthLogan Blankenship, Uday P Pratap, Xue Yang, et al.
Cell Death Discovery|August 17, 2021
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancerWeiwei Tang, Kumaraguruparan Ramasamy, Sureshkumar M A Pillai, et al.
Cancer Letters|September 15, 2023
Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancerPrabhakar Pitta Venkata, Sridharan Jayamohan, Yi He, et al.
Cancer Research|August 11, 2022
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast CancerKristin A Altwegg, Suryavathi Viswanadhapalli, Monica Mann, et al.
Communications Biology|October 30, 2021
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancerMengxing Li, Suryavathi Viswanadhapalli, Bindu Santhamma, et al.
Nature Cancer|May 20, 2024
Author Correction: Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stressXihui Liu, Suryavathi Viswanadhapalli, Shourya Kumar, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Neuro-Oncology Advances|September 6, 2021
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastomaUday P Pratap, Gangadhara R Sareddy, Zexuan Liu, et al.
Science (New York, N.Y.)|June 27, 2020
Metalens-array-based high-dimensional and multiphoton quantum sourceLin Li, Zexuan Liu, Xifeng Ren, et al.
Breast Cancer Research : BCR|April 9, 2022
SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistanceZexuan Liu, Junhao Liu, Behnam Ebrahimi, et al.
Molecular Oncology|October 19, 2023
PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesisXue Yang, Zexuan Liu, Weiwei Tang, et al.
Cancers|November 11, 2022
Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer GrowthLogan Blankenship, Uday P Pratap, Xue Yang, et al.
Cell Death Discovery|August 17, 2021
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancerWeiwei Tang, Kumaraguruparan Ramasamy, Sureshkumar M A Pillai, et al.
Cancer Letters|September 15, 2023
Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancerPrabhakar Pitta Venkata, Sridharan Jayamohan, Yi He, et al.
Cancer Research|August 11, 2022
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast CancerKristin A Altwegg, Suryavathi Viswanadhapalli, Monica Mann, et al.
Communications Biology|October 30, 2021
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancerMengxing Li, Suryavathi Viswanadhapalli, Bindu Santhamma, et al.
Nature Cancer|May 20, 2024
Author Correction: Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stressXihui Liu, Suryavathi Viswanadhapalli, Shourya Kumar, et al.
Pageof 6